Speaker Profile
M.D., Ph.D., Director, MSK
Biography
Dr. Pedram Razavi is a medical oncologist and physician-scientist at Memorial Sloan Kettering Cancer Center (MSK), specializing in precision oncology for breast cancer. He serves as Director of the Breast Cancer Translational Program and Molecular Tumor Board, and Director of Liquid Biopsy and Cancer Genomics for the MSK Biomarker Development Program. His research focuses on integrative clinicogenomic approaches and circulating tumor biomarkers to characterize breast cancer at both systemic and molecular levels and to expand the clinical utility of liquid biopsy technologies.Dr. Razavi earned his MD from Tehran University of Medical Sciences and his MPH and PhD in cancer epidemiology from the University of Southern California. He completed a postdoctoral fellowship at the Channing Laboratory, an internal medicine residency at USC, and a medical oncology fellowship at MSK, where he also conducted postdoctoral research in cancer genomics in the lab of Dr. José Baselga.
Session Abstract – PMWC 2026 Silicon Valley
Track Chair: Adrian Lee, University of Pittsburgh
PMWC Award Ceremony Honorees
• Dennis J. Slamon, UCLA
Neoadjuvant to Adjuvant MRD: How Early Is Early Enough?
• Chair: Angela DeMichele, UPenn
• Halla Nimeiri, Tempus
• Aparna Parikh, Harvard
• Minetta Liu, Natera
Serial ctDNA-Guided Therapy Switching (SERENA-6 & Beyond)
• Chair: Pedram Razavi, MSK
Multi-Omics Monitoring Beyond Variants: Methylation, Fragmentomics, EV/ctRNA
• David T. Miyamoto, Massachusetts General Hospital
• Maximilian Diehn, Stanford
From Validation to Payment: Coverage Pathways That Work
• Mark Stewart, Friends of Cancer Research
From Validation to Payment: Coverage Pathways That Work
• Mark Stewart, Friends of Cancer Research
• Hilary Gee Goeckner, American Cancer Society (ACS)
• Sally Werner, Cancer Support Community
• Gabriel A. Bien-Willner, Palmetto GBA
